dpp 4 inhibitor and glp 1 receptor agonist combination Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Table 2 from DPP- 4

# # # Disclosures: Rohit Loomba, MD, is a consultant or advisory board member for Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics

GLP-1 RAs also have a series of beneficial multifactorial effects beyond glycaemic control that include reduction of body weight and improvement of cardiovascular (CV) outcomes [14]

95% CI, 0.46-0.61

Trends Endocrinol Metab 31(6):410421

Additional studies are needed to determine whether SGLT2 inhibitors can meaningfully delay kidney disease progression in people with non-albuminuric or non-proteinuric DKD

From there, the question becomes what the medication is actually doing for that patient